Chevallard Daniel R. 4

What Happened

Daniel R. Chevallard, Chief Financial Officer of LENZ Therapeutics, purchased 7,500 shares of LENZ on March 27, 2026. The shares were acquired at $8.57 per share for a total cost of $64,275. The transaction is reported as a purchase (transaction code P) and was executed as an open-market/private purchase.

Key Details

• Transaction date and price: 2026-03-27, 7,500 shares at $8.57 each.
• Total value: $64,275.
• Transaction type/code: Purchase (P) — open-market/private purchase.
• Shares owned after the transaction: Not specified in the Form 4 filing.
• Footnotes/plan: No 10b5-1 plan, tax-withholding, or other footnotes indicated in the filing.
• Filing: Form 4 filed with the SEC on 2026-03-30 reporting the 3/27 transaction; the filing shows no late-filing flag.

Context

This was a straightforward insider purchase (not an option exercise, gift, or award). Insider purchases are often viewed by investors as a sign of alignment with shareholders, though they are just one data point and do not guarantee future stock performance. The purchase size (~$64k) is modest; consider this alongside company fundamentals and other insider activity when evaluating its significance.